Alzheimer's Disease

Welcome to PT 635 Pathophysiology of Complex Patient Problems This is a wiki created by and for the students in the School of Physical Therapy at Bellarmine University in Louisville KY. Please do not edit unless you are involved in this project, but please come back in the near future to check out new information!!

Original Editors - Students from Bellarmine University's Pathophysiology of Complex Patient Problems project.

Lead Editors - Your name will be added here if you are a lead editor on this page.  Read more.

Definition/Description

Alzheimer's Disease is characterized by cortical atrophy and loss of neurons, particularly in the parietal and temporal lobes. Also with loss of brain mass there is an enlargement of the ventricals of the brain.² The changes in the brain tissue slowly cause changes in the person. Often it results in Alzheimer's dementia, however some people progress differently.

Prevalence

Approximately 4 - 4.5 million people have Alzheimer's Disease in the United States and about 8 million affected around the world. It is expected that by 2050 that number will have increased almost three fold to around 13.2 million. The known prevalence is 6% in people over the age of 65, 20% in people over the age of 80, and more than 95% in those 95 years of age.¹

Characteristics/Clinical Presentation

The progression of Alzheimer's Disease is continuous and generally does not fluctuate or improve. Often times the early symptoms can be missed or overlooked because they can be misinterpreted as signs of the natural aging process.

Stages of Alzheimer's Disease²

Stage 1

• memory loss
• lack of spontaneity
• subtle personality changes
• disorientation to time and date

Stage 2

• impaired cognition and abstract thinking
• restlessness and agitation
• wandering, "sundown syndrome"
• inability to carry out activities of daily living
• impaired judgment
• inappropriate social behavior
• lack of insight, abstract thinking
• repetitive behavior
• voracious appetite

Stage 3

• emaciation, indifference to food
• inability to communicate
• urinary and fecal incontinence
• seizures
  
  

Associated Co-morbidities

add text here

Medications

Commonly Used Medications for Alzheimer's Disease¹

Donepezil - (Aricept) has only modest benefits, but it does help slow loss of function and reduce caregiver burden. It works equally in patients with and without apoipoprotein E4. It may even have some advantage for patients with moderate to severe Alzheimer's Disease.

Rivastigmine - (Exelon) targets two enzymes (the major one, acetylcholinesterase, and butyrylcholinesterase). This agent may be particularly beneficial for patients with rapidly progressing disease. This drug has slowed or slightly improved disease status even in patients with advanced disease. (Rivastigmine may cause significantly more side effects than donepezil, including nausea, vomiting, and headache.)

Galantamine - (Reminyl) Galantamine not only protects the cholinergic system but also acts on nicotine receptors, which are also depleted in Alzheimer's Disease. It improves daily living, behavior, and mental functioning, including in patients with mild to advanced-moderate Alzheimer's Disease and those with a mix of Alzheimer's and vascular dementia. Some studies have suggested that the effects of galantamine may persist for a year or longer and even strengthen over time.

Tacrine - (Cognex) has only modest benefits and has no benefits for patients who carry the apolipoprotein E4 gene. In high dosages, it can also injure the liver. In general, newer cholinergic-protective drugs that do not pose as great a risk for the liver are now used for Alzheimer's.

Memantine - (Namenda) targeted at the N-methyl-dasparate receptor, is used for moderate to severe Alzheimer's.

Selegiline - (Eldepryl) is used for treatment of Parkinson's disease, and it appears to increase the time before advancement to the next stage of disability.

Diagnostic Tests/Lab Tests/Lab Values

add text here

Causes

There is no know cause of Alzheimer's Disease.

Systemic Involvement

add text here

Medical Management (current best evidence)

add text here

Physical Therapy Management (current best evidence)

add text here

Alternative/Holistic Management (current best evidence)

add text here

Differential Diagnosis

add text here

Case Reports

add links to case studies here (case studies should be added on new pages using the case study template)

Recent Related Research (from Pubmed)

see tutorial on Adding PubMed Feed

http://eutils.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=1xONNp6hzwmbFtho8j3NkZprYu6eCHOfsB1HYiGUxIrEvzXs3W

References

see adding references tutorial.

1. Goodman C, Fuller K. Pathology Implications for the Physical Therapist. St. Louis, Missouri: Saunders Elsevier; 2009.

2. Porth C. Pathopysiology Concepts of Altered Health States. Philadelphia PA: Lippincott & Wilkins; 2005.

3. Goodman C, Snyder T. Differential Diagnosis for Physical Therapists Screening for Referal. St. Louis, Missouri: Saunders Elsevier; 2007.

4. Alzheimer's Association. 2010. Available at: http://www.alz.org/index.asp . Accessed March 1, 2010.

5. Alzheimer's Disease Fact Sheet. U.S. National Institutes of Health National Institute on Aging. 2010. Available at: http://www.nia.nih.gov/Alzheimers/Publications/adfact.htm . Accessed March 1, 2010.